|Title:||Therapeutic compositions for intranasal administration which include KETOROLAC|
|Abstract:||An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.|
|Inventor(s):||Santus; Giancarlo (Milan, IT), Bottoni; Giuseppe (Bergamo, IT), Bilato; Ettore (Padova, IT)|
|Assignee:||Recordati Ireland Limited (IE)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Formulation; Compound; Dosage form;|
Back Citations: 20th percentile
Forward Citations: 0th percentile
|Patent Number||Expiration Date|
|7,476,689||January 13, 2017|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Italy||MI91A2024||Jul 22, 1991|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.